8-K: Shineco Subsidiary Acquires 51% Stake in InfiniClone Limited for $19.9 Million Plus Stock

Shineco, Inc. subsidiary, Shineco Life Science Group Hong Kong Co., Limited, enters into a share purchase agreement to acquire 51% of InfiniClone Limited for cash and stock.

Summary

• Shineco, Inc., through its subsidiary Shineco Life Science Group Hong Kong Co., Limited, has agreed to acquire 51% of InfiniClone Limited.
• The acquisition will be completed through a share purchase agreement (SPA) with Dr. Lim Kah Meng, the sole shareholder of InfiniClone.
• The consideration for the 51% stake includes US$19,895,600 in cash and 3,450,000 shares of Shineco's common stock.
• The share issuance is subject to the terms and conditions outlined in the SPA and has been approved by Shineco's board of directors.
• The cash payment and share transfer are expected to occur within 90 days of the SPA execution.
• The agreement includes customary obligations and rights for both parties.
• InfiniClone Limited was incorporated under the laws of Hong Kong on March 11, 2025.
• The parties have agreed that the value of the SISI restricted shares for the purpose of this consideration payment shall be USD 1.20 per share.
• The Parties mutually acknowledge and agree that the Consideration has been determined to be fair, reasonable, and legitimate based on a valuation report prepared by Zhongli Asset Appraisal (Beijing) Co., Ltd., an independent third-party valuer, dated February 26, 2025.

Sentiment

Score: 7

Explanation: The announcement is a straightforward description of an acquisition, suggesting a neutral to slightly positive outlook for Shineco's growth strategy.

Positives

• Shineco expands its business through the acquisition of a majority stake in InfiniClone Limited.
• The acquisition provides Shineco with access to InfiniClone's assets and operations.
• The SPA includes customary protections and obligations for Shineco.
• The parties have agreed that the value of the SISI restricted shares for the purpose of this consideration payment shall be USD 1.20 per share.
• The Parties mutually acknowledge and agree that the Consideration has been determined to be fair, reasonable, and legitimate based on a valuation report prepared by Zhongli Asset Appraisal (Beijing) Co., Ltd., an independent third-party valuer, dated February 26, 2025.

Risks

• The transaction is subject to customary closing conditions and may not be completed.
• The value of Shineco's common stock could fluctuate, affecting the overall consideration.
• InfiniClone's performance may not meet expectations, impacting the return on investment.
• If the net profit of the Company for any financial year falls below the minimum threshold (inclusive of instances whereby net profit is less than zero), the Seller shall compensate the Purchaser by paying an amount equal to the shortfall in net profit, proportionate to the Purchasers equity ownership of 51% of the Company.

Future Outlook

The cash payment and share transfer are expected to occur within 90 days of the SPA execution.

Management Comments

• Each of the SPA, the transaction contemplated thereby and the issuance of the Shares has been approved by the Company's board of directors.

Industry Context

Acquisitions in the life science sector are common as companies seek to expand their product portfolios and market reach.

Comparison to Industry Standards

• Deal terms appear standard for acquisitions of this type, involving a mix of cash and stock consideration.
• Valuation metrics would need to be compared to similar transactions to assess the fairness of the price.

Stakeholder Impact

• Shareholders of Shineco will see dilution from the issuance of new shares.
• InfiniClone's employees may experience changes as a result of the acquisition.
• Customers of both companies may benefit from expanded product offerings.

Next Steps

• Completion of the cash payment and share transfer within 90 days.
• Fulfillment of customary obligations and rights outlined in the SPA.

Key Dates

Keywords

acquisition, share purchase agreement, InfiniClone Limited, Shineco Life Science, Shineco Inc., equity interest